Literature DB >> 10575146

Genotype and allele frequency of a 32-base pair deletion mutation in the CCR5 gene in various ethnic groups: absence of mutation among Asians and Pacific Islanders.

Y Lu1, V R Nerurkar, W M Dashwood, C L Woodward, S Ablan, C M Shikuma, A Grandinetti, H Chang, H T Nguyen, Z Wu, Y Yamamura, W O Boto, A Merriwether, T Kurata, R Detels, R Yanagihara.   

Abstract

BACKGROUND: A 32-base pair (bp) deletion mutation in the beta-chemokine receptor CCR5 gene has been associated with resistance against human immunodeficiency virus type 1 (HIV-1) infection and disease. Large-scale studies conducted among Caucasians indicate that individuals who are homozygous for this deletion mutation (D32/D32) are protected against HIV-1 infection despite multiple high-risk exposures, whereas CCR5/ D32 heterozygotes have a slower progression to acquired immunodeficiency syndrome (AIDS).
OBJECTIVE: To determine the genotype and allele frequencies of the CCR5 gene 32-bp deletion mutation among ethnically diverse non-Caucasian populations.
METHODS: DNA, extracted from blood collected between 1980 and 1997 from 1912 individuals belonging to various ethnic groups, including 363 Caucasians, 303 Puerto Rican Hispanics, 150 Africans, 606 Asians, and 490 Pacific Islanders, were analyzed for the CCR5 gene 32-bp deletion mutation by a polymerase chain reaction (PCR)-based assay, using an oligonucleotide primer pair designed to discriminate CCR5 alleles without restriction endonuclease analysis.
RESULTS: The comparative frequency of CCR5/D32 heterozygosity was 61 of 363 (16. 8%) in Caucasians, 17 of 303 (5.6%) in Puerto Rican Hispanics, 9 of 490 (1.8%) in Pacific Islanders, 0 of 606 (0%) in Asians, and 0 of 150 (0%) in Africans.
CONCLUSIONS: The data confirm the high frequency of CCR5/D32 heterozygosity among Caucasians. Intermediate and low-level D32 allele frequencies among Puerto Rican Hispanics and Hawaiians could be attributed to recent European Caucasian gene flow. By contrast, the inability to detect the D32 allele among Asians and other Pacific Islander groups suggests that other mechanisms are responsible for resistance to HIV-1 infection in these populations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10575146     DOI: 10.1016/s1201-9712(99)90022-x

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  11 in total

Review 1.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

2.  C-C chemokine receptor 2 and C-C chemokine receptor 5 genotypes in patients treated for chronic hepatitis C virus infection.

Authors:  M Tevfik Dorak; Gbolahan O Folayan; Santosh Niwas; Dirk J van Leeuwen; Leland J Yee; Jianming Tang; Richard A Kaslow
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

3.  Association analysis and allelic distribution of deletion in CC chemokine receptor 5 gene (CCR5Δ32) among breast cancer patients of Pakistan.

Authors:  Faria Fatima; Saima Saleem; Abdul Hameed; Ghulam Haider; Syed Aqib Ali Zaidi; Madiha Kanwal; Sitwat Zehra; Abid Azhar
Journal:  Mol Biol Rep       Date:  2019-03-08       Impact factor: 2.316

4.  CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission.

Authors:  Jean K Lim; David H McDermott; Andrea Lisco; Gregory A Foster; David Krysztof; Dean Follmann; Susan L Stramer; Philip M Murphy
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

5.  Chemokine (CCR) and fractalkine (CX3CR) receptors and end stage renal disease.

Authors:  Minal Borkar; Gaurav Tripathi; Raj Kumar Sharma; Satya Narayan Sankhwar; Suraksha Agrawal
Journal:  Inflamm Res       Date:  2010-12-04       Impact factor: 4.575

6.  CC chemokine receptor 5 delta32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia.

Authors:  Hermann E Wasmuth; Alexa Werth; Tobias Mueller; Thomas Berg; Christoph G Dietrich; Andreas Geier; Ramin Schirin-Sokhan; Carsten Gartung; Johann Lorenzen; Siegfried Matern; Frank Lammert
Journal:  J Mol Med (Berl)       Date:  2003-12-13       Impact factor: 4.599

7.  Association study of CCR5 delta 32 polymorphism among the HLA-DRB1 Caucasian population in Northern Paraná, Brazil.

Authors:  Sandra Marcia Muxel; Sueli Donizete Borelli; Marla Karine Amarante; Julio Cesar Voltarelli; Mateus Nobrega Aoki; Carlos Eduardo Coral de Oliveira; Maria Angelica Ehara Watanabe
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

8.  Genetically edited CD34+ cells derived from human iPS cells in vivo but not in vitro engraft and differentiate into HIV-resistant cells.

Authors:  Maelig G Morvan; Fernando Teque; Lin Ye; Mary E Moreno; Jiaming Wang; Scott VandenBerg; Cheryl A Stoddart; Yuet Wai Kan; Jay A Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-18       Impact factor: 11.205

9.  Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection.

Authors:  William G Glass; Jean K Lim; Rushina Cholera; Alexander G Pletnev; Ji-Liang Gao; Philip M Murphy
Journal:  J Exp Med       Date:  2005-10-17       Impact factor: 14.307

10.  The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro.

Authors:  Janet J Maguire; Katie L Jones; Rhoda E Kuc; Murray C H Clarke; Martin R Bennett; Anthony P Davenport
Journal:  Cardiovasc Res       Date:  2013-12-09       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.